Small molecule inhibitors of NEF-mediated immune evasion
Active Grant Awarded
- Award ID
- R01AI198059
- Recipient
-
Florida State University UEI JF2BLNN4PJC3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $800,229
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 8% complete
- Place of performance
- Tallahassee, FL 32306, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded Florida State University $800,229 under Grant R01AI198059 on July 7, 2026, through the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds small molecule inhibitors of HIV-1 Nef, a master regulator of immune evasion that downregulates MHC-I and CD4 so infected cells escape cytotoxic T lymphocytes and antibody-dependent cellular cytotoxicity by natural killer cells. The project aims to revitalize CTL and NK cell activity against infected cells. Four in vitro assays for screening small molecule libraries have been developed and optimized, two of which are orthogonal to each other and both capable of identifying inhibitors.
Veterans Medical Research Foundation of San Diego receives a sub-award dated August 13, 2026, to perform cell culture experiments assessing the activity and toxicity of Nef inhibitors identified and optimized by Dr. Jia and collaborators.
The period of performance runs from the July 7, 2026 award date through June 30, 2031. Place of performance is Tallahassee, Florida 32306.
Description
- Abstract
- The currently available antiretrovirals can effectively control HIV-1 replication and thus prevent disease pro- gression to aids. Such antiretroviral treatment (art), however, cannot eradicate the infection. Latently infect- ED cells persist through art and, if art is stopped, will lead to rebound of viral replications within weeks. In- fected individuals therefore need to take medications for the entire life span and consequently suffer from drug resistance as well as severe side effects including cardiovascular complications, metabolic disorders, and NEU- rocognitive damage. Novel antiretrovirals that could eliminate HIV-1 infection and cure the disease is thus high- LY desired. IT is believed that HIV cure could be possibly achieved through empowering host immune cells to recognize and kill HIV-1-infected cells. One significant barrier here, however, is that HIV-1 has evolved mech- anisms that enable infected cells to evade host immunity. A key player here is the HIV-1 NEF protein. NEF is a master regulator of HIV-1 immune evasion. By downregulating MHC-I from the surface of the host cell, NEF DIS- rupts host cell's antigen presentation, which then allows the infected cell to evade immune surveillance by host cytotoxic T lymphocytes (CTLS). NEF also downregulates CD4 from the cell surface; this benefits the infected cell in several ways including evading killing by natural killer (NK) cells through antibody-dependent cellular cytotoxicity (ADCC). Inhibition of these NEF functions should revitalize both CTLS and NK cells, empowering them to find and kill HIV-1 infected cells. This project is aimed at developing such inhibitors and thus overcome the barrier of viral immune evasion to facilitate the cure. Four in vitro assays have been developed and opti- mized for screening small molecule libraries to find inhibitors. Two assays, orthogonal to each other, are both capable of identifying inhibitors that can block NEF's activity on MHC-I and CTLS (having two orthogonal assays here allows cross-validation of hits to ensure discovery of true inhibitors). Another two assays, also orthogonal to each other, are capable of finding inhibitors that can block NEF's activity on CD4 and ADCC. These assays have been tested in a proof-of-concept screen against a medium-sized compound library. All four assays per- formed excellently, indicating their suitability for high-throughput screening. A HIT compound has been found from this modest screen and was subsequently validated through concentration-dependent studies in vitro. Building on these promising results, we now propose to carry out-using our developed assays and the estab- lished workflow-large-scale library screens to identify inhibitors against the two targeted NEF functions (aim 1). We will then use both in vitro and cell-based assays to characterize inhibitors and identify those with out- standing potency and efficacy (aim 2). We will also solve high-resolution structures of inhibitor-NEF complexes and then use the structural information obtained to guide chemical derivatization of lead compounds (aim 3). Upon completion of the project, we will obtain potent inhibitors of NEF-mediated immune evasion, ready for FUR- ther development into real-world antiretrovirals to facilitate HIV cure.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Veterans Medical Research Foundation Of San Diego | $236,037 |
Quick answers
Who received award R01AI198059?
R01AI198059 was awarded to Florida State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 7, 2026.
How much is award R01AI198059 worth?
$800,229 has been obligated on R01AI198059.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award